Drug Eluting Balloons (DEBs) - Global Market Trajectory & Analytics

Global Drug Eluting Balloons (DEBs) Market to Reach $1.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Drug Eluting Balloons (DEBs) estimated at US$400.1 Million in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 24.1% over the period 2020-2027. Peripheral DEBs, one of the segments analyzed in the report, is projected to record 25.3% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Coronary DEBs segment is readjusted to a revised 20.7% CAGR for the next 7-year period.



The U.S. Market is Estimated at $119.8 Million, While China is Forecast to Grow at 23.4% CAGR

The Drug Eluting Balloons (DEBs) market in the U.S. is estimated at US$119.8 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$312.4 Million by the year 2027 trailing a CAGR of 23.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 21.7% and 20.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 16.7% CAGR.

Select Competitors (Total 42 Featured):

• Acrostak Int. Distr. Sarl
• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Cardionovum GmbH
• Cook Medical, Inc.
• Eurocor GmbH
• Medtronic PLC
• Spectranetics Corporation